Author

J. A. Copland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Alasonyalilar Demirer· 1 shared A. J. Finch· 1 shared A. M. Magee· 1 shared A. Rio-Machin· 1 shared A. von Kriegsheim· 1 shared A. Zubair· 1 shared B. L. Kimball· 1 shared B. M. Cavaco· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Alasonyalilar Demirer

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Optimized CART Cell Therapy for Metastatic Aggressive Thyroid Cancer

C. Manriquez-Roman, E. L. Siegler, J. J. Gleba, T. N. Huynh, G. E. DeFranco, A. Alasonyalilar Demirer, M. L. Pawlush, M. Redig, S. M. Klinge, L. K. Mai, J. L. Miller, E. E. Miller, B. L. Kimball, E. E. Tapper, R. L. Sakemura, , S. S. Kenderian

This paper develops a TSHR-targeted CART cell therapy for thyroid cancer and shows that combining it with MAPK inhibitors improves antitumor efficacy in dedifferentiated thyroid cancers.

bioRxiv · Mar 15, 2024 · PreprintImmunology

SCD inhibition eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy

V. Dembitz, H. Lawson, R. Burt, C. Philippe, S. C. James, S. Atkinson, J. Durko, L. M. Wang, J. Campos, A. M. Magee, K. Woodley, M. J. Austin, A. Rio-Machin, P. Casado-Izquierdo, F. Bewicke-Copley, , P. Gallipoli

SCD inhibition induces AML cell death and synergizes with chemotherapy to prolong survival in murine AML models.

bioRxiv · Aug 2, 2023Cancer Biology

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas

J. M. Pita, E. Raspe, K. Coulonval, M. Decaussin-Petrucci, M. Tarabichi, G. Dom, F. Libert, L. Craciun, G. Andry, L. Wicquart, E. Leteurtre, C. Tresallet, L. A. Marlow, J. A. Copland, C. Durante, , P. P. Roger

This study shows that CDK4 phosphorylation status predicts response to CDK4/6 inhibitors in thyroid carcinomas and supports combining them with BRAF/MEK inhibitors to prevent resistance.

bioRxiv · Jun 5, 2023Cancer Biology

Stearoyl-CoA desaturase mediated monounsaturated fatty acid availability supports humoral immunity

X. Zhou, X. Zhu, C. Li, Y. Li, Z. Ye, V. M. Shapiro, J. A. Copland, T. Hitosugi, D. A. Bernlohr, J. Sun, H. Zeng

The paper shows that monounsaturated fatty acids (MUFA) are essential for B cell function and humoral immunity, with SCD-mediated MUFA production supporting early B cell development and germinal center formation.

bioRxiv · Apr 22, 2020Immunology